Erasca, Inc. Intellectual Property Contracts & Agreements
7 Contracts & Agreements
- License Agreements (7 contracts)
- License Agreement, dated May 14, 2024, by and between Medshine Discovery Inc., and Erasca, Inc (Filed With SEC on August 12, 2024)
- License Agreement, dated May 15, 2024, by and between Guangzhou Joyo Pharmatech Co., Ltd., and Erasca, Inc (Filed With SEC on August 12, 2024)
- First Amendment to Exclusive License Agreement, dated August 7, 2023, by and between Novartis Pharma AG and the Registrant (Filed With SEC on November 9, 2023)
- Amended and Restated License Agreement, dated November 23, 2020, by and among the Registrants wholly-owned subsidiaries, ASN Product Development, Inc. and Asana BioSciences, LLC (Filed With SEC on June 25, 2021)
- Exclusive License Agreement, dated March 12, 2020, by and between Katmai Pharmaceuticals, Inc. and the Registrant (Filed With SEC on June 25, 2021)
- License Agreement, dated February 18, 2020, by and between NiKang Therapeutics, Inc. and the Registrant (Filed With SEC on June 25, 2021)
- Exclusive License Agreement, dated December 21, 2018, by and between The Regents of the University of California and the Registrant, as amended (Filed With SEC on June 25, 2021)
